A Study of Anti-PD1 Antibody-activated TILs in Non-small Cell Lung Cancer

Summary

This study was a phase I/II trial initiated by the investigator to evaluate the safety and tolerability of anti-PD-1 antibody-activated TILs combined with adjuvant chemotherapy in participants with stage II-IIIA non-small cell lung cancer. 20 participants were enrolled and anti-PD-1 antibody-activated TILs was infused into participants after the final cycle chemotherapy to assess the safety and disease-free survival.

Timeline

Start

2019-02-19

Primary completion

2019-12-31

Completion

2021-12-31

Drugs

Indications